Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...
Publications
View AllAffiliated Researchers
Institution Info
- Type
- healthcare
- Country
- US
- Publications
- 1
- Citations
- 2,716
External Links
Identifiers
- ROR
- https://ror.org/03n7vd314